PATENT CLAIM ANALYSIS

Application Number: 16356172
Application Type: Utility
Filing Date: 2019-03
Publication Date: 2019-09
Patent Classification: ["514", "210160"]

Abstract:
The present invention relates to compounds according to Formula I and pharmaceutically acceptable salts thereof. Such compounds can be used in the treatment of RORgammaT-mediated diseases or conditions.

Claim (Index 63):
A method of treating cancer in a subject, comprising administering to the subject an amount of the following compound that is effective to treat the cancer: or a pharmaceutically acceptable salt thereof; wherein the cancer is a B-cell lymphoma, non-Hodgkin lymphoma, colon cancer, pancreatic cancer, breast cancer, ovarian cancer, prostate cancer, squamous cell carcinoma, basal cell carcinoma, adenocarcinoma, sweat gland carcinoma, sebaceous gland carcinoma, lung cancer, leukemia, bladder cancer, stomach cancer, cervical cancer, testicular cancer, skin cancer, rectal cancer, thyroid cancer, kidney cancer, uterus cancer, esophagus cancer, liver cancer, an acoustic neuroma, oligodendroglioma, meningioma, neuroblastoma, or retinoblastoma.

Metadata:
- Claim Count in Document: 65.0
- Percentile: 99.0
- Lexical Diversity: 1.11111
- Patent Class: 514.0
- Transitional Phrase Type: open
- Component Type: 1
- Foreign Priority: False
- Related Applications: ['15770256', '15770255', '15549465', '14421057', '14421062']

Analysis Scores:
- 35 USC 101 Eligibility (BERT): 0.7671970667043398
- 35 USC 102 Novelty (BERT): 0.5670813130080841
- Combined Prediction Score: 0.7471854913347143
- Mean Citation Score: 405.479048
- Max Citation Score: 474.67447
- Similarity Product: 331.2334945371312

Labels:
- Claim Label 101: 1
- Claim Label 102: 1
- Claim Label 103: 1
- Claim Label 112: 1
- Combined Label: 1
- Label 101 Adjusted: 1

Dataset: test